ÂÜÀòÂÒÂ×

Martin serves as Integral Molecular’s primary advisor on the design of antibody preclinical efficacy and safety studies, enabling submission of investigational new drug (IND) applications. He is the CEO of Opsidio LLC, and brings over 30 years of drug development experience, including a career in academic medicine, biotech, and the pharmaceutical industry. Previously, he served as the Chief Medical Officer of two venture-backed biotechs and VP of Clinical Research for Aventis Behring (now CSL). He has been responsible for numerous patent filings, 9 IND filings, negotiations with the FDA, and globally overseeing over 30 clinical studies involving biologics and small molecule therapeutics.